Research Article
Serum Uric Acid Is Associated with the Progression of Left Ventricular Diastolic Dysfunction in Apparently Healthy Subjects
Table 1
Baseline characteristics grouped by quartiles of serum uric acid.
| | SUA (μmol/L) | ≤282 | 283~ 340 | 341~ 393 | ≥394 | value | | n | 272 | 269 | 273 | 268 |
| | Follow-up time, months | | | | | 0.400 | | Male sex | 68 (25.0) | 138 (51.3) | 230 (84.2) | 251 (93.7) | <0.001 | | Age, years | | | | | <0.001 | | Hypertension | 23 (8.5) | 25 (9.3) | 23 (8.4) | 19 (7.1) | 0.831 | | Diabetes | 33 (12.1) | 41 (15.2) | 45 (16.5) | 44 (16.4) | 0.449 | | Smoking status | 23 (8.5) | 53 (19.7) | 84 (30.8) | 93 (34.7) | <0.001 | | BMI, kg/m2 | | | | | <0.001 | | Systolic BP, mmHg | | | | | 0.004 | | Diastolic BP, mmHg | | | | | <0.001 | | HbA1c, % | | | | | 0.003 | | Fasting glucose, mmol/L | 4.88 (4.53~5.34) | 5.00 (4.61~5.51) | 5.09 (4.70~5.59) | 5.10 (4.70~5.59) | 0.002 | | Postprandial glucose, mmol/L | 6.64 (5.66~7.74) | 7.06 (5.70~8.73) | 6.92 (5.84~8.62) | 7.03 (6.03~8.30) | 0.169 | | Fasting insulin, μU/L | 6.33 (4.68~9.05) | 7.46 (4.95~10.72) | 8.46 (5.65~12.42) | 8.93 (6.05~13.04) | <0.001 | | Postprandial insulin, μU/L | 36.37 (22.49~59.03) | 43.54 (24.48~64.26) | 44.22 (26.12~76.03) | 44.98 (28.20~78.83) | 0.028 | | HOMA-IR | 1.41 (0.96~2.06) | 1.73 (1.06~2.52) | 2.00 (1.28~2.98) | 2.06 (1.38~ 3.07) | <0.001 | | Alaine aminotransferase, IU/L | | | | | <0.001 | | Aspartate aminotransferase, IU/L | | | | | 0.143 | | Triglyceride, mmol/L | 1.04 (0.78~1.35) | 1.18 (0.89~1.68) | 1.44 (1.06~1.93) | 1.75 (1.23~2.52) | <0.001 | | Total cholesterol, mmol/L | | | | | 0.179 | | HDL cholesterol, mmol/L | | | | | <0.001 | | LDL cholesterol, mmol/L | | | | | 0.052 | | Serum creatine μmol/L | | | | | <0.001 | | Blood urea nitrogen, mmol/L | | | | | <0.001 | | eGFR, mL/min/1.732m2 | | | | | <0.001 | | hsCRP, mg/L | 0.39 (0.21~1.18) | 0.65 (0.29~1.17) | 0.99 (0.42~2.25) | 1.62 (0.65~3.64) | <0.001 | | Aspirin | 15 (5.5) | 20 (7.4) | 16 (5.9) | 11 (4.1) | 0.425 | | P2Y12 inhibitor | 21 (7.7) | 16 (5.9) | 12 (4.4) | 10 (3.7) | 0.174 | | Beta blocker | 16 (5.9) | 19 (7.1) | 16 (5.9) | 8 (3.0) | 0.195 | | ACEI/ARB | 13 (4.8) | 13 (4.8) | 15 (5.5) | 12 (4.5) | 0.956 | | Calcium channel blocker | 12 (4.4) | 6 (2.2) | 7 (2.6) | 7 (2.6) | 0.430 | | Statin | 13 (4.8) | 26 (9.7) | 22 (8.1) | 16 (6.0) | 0.122 | | OHA | 10 (3.7) | 17 (6.3) | 12 (4.4) | 10 (3.7) | 0.414 | | Insulin | 4 (1.5) | 6 (2.2) | 2 (0.7) | 3 (1.1) | 0.492 |
|
|
Data are expressed as or median (interquartile range). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; BP: blood pressure; eGFR: estimated glomerular filtration rate; HbA1c: glycated hemoglobin A1c; HDL: high-density lipoprotein; HOMA-IR: homeostasis model assessment-estimated insulin resistance; hsCRP: high-sensitivity C-reactive protein; LDL: low-density lipoprotein; OHA: oral hypoglycemic agent; SUA: serum uric acid. |
